# Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

> **NCT07051850** · — · RECRUITING · sponsor: **Sung-Soo Park** · enrollment: 174 (estimated)

## Conditions studied

- Multiple Myeloma, Relapsed
- Multiple Myeloma (MM)

## Interventions

- **DRUG:** Bispecific antibody
- **DRUG:** Antibody-Drug Conjugate
- **DRUG:** Monoclonal antibody
- **DRUG:** Proteasome Inhibitor
- **DRUG:** IMiD treatment
- **DRUG:** CAR-T Therapy

## Key facts

- **NCT ID:** NCT07051850
- **Lead sponsor:** Sung-Soo Park
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-14
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 174 (ESTIMATED)
- **Last updated:** 2025-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07051850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07051850, "Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07051850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*